NCT07373470Recruiting
An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
Genotype-guided Comprehensive Medication Management to Improve Depression Outcomes in Pennsylvania
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes. The primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care. Participants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 9 Sept 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Pittsburgh
- Diseases
- Depression
- NCT number
- NCT07373470
What you commit to
- Study type: Interventional
- Planned participants: 220
- From 9 Sept 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously
Other illness
- Untreated sleep disorder (patient-reported)
Other
- Inability to receive CMM at specific pharmacy/pharmacist
- Comorbid diagnosis of schizophrenia (patient-reported)
Who the study is looking for
- At targeted community pharmacy for:
- New prescription or change in dose/schedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR
- Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription/change in SNRI (desvenlafaxine, duloxetine, and venlafaxine) / bupropion.
- Depressive symptoms confirmed by PHQ8 assessment (\>5 indicating at least mild depressive symptoms)
- UPMC patient (or able/willing to become one) and has UPMC provider (or able/willing to obtain one)
- Signed consent to join Pitt+Me Discovery biobanking research study.
- English-speaking
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.